Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors.


Journal

ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589

Informations de publication

Date de publication:
22 01 2019
Historique:
pubmed: 28 12 2018
medline: 22 1 2020
entrez: 28 12 2018
Statut: ppublish

Résumé

Cancer is one of the main causes of death around the world, lacking efficient clinical treatments that generally present severe side effects. In recent years, various nanosystems have been explored to specifically target tumor tissues, enhancing the efficacy of cancer treatment and minimizing the side effects. In particular, bladder cancer is the ninth most common cancer worldwide and presents a high survival rate but serious recurrence levels, demanding an improvement in the existent therapies. Here, we present urease-powered nanomotors based on mesoporous silica nanoparticles that contain both polyethylene glycol and anti-FGFR3 antibody on their outer surface to target bladder cancer cells in the form of 3D spheroids. The autonomous motion is promoted by urea, which acts as fuel and is inherently present at high concentrations in the bladder. Antibody-modified nanomotors were able to swim in both simulated and real urine, showing a substrate-dependent enhanced diffusion. The internalization efficiency of the antibody-modified nanomotors into the spheroids in the presence of urea was significantly higher compared with antibody-modified passive particles or bare nanomotors. Furthermore, targeted nanomotors resulted in a higher suppression of spheroid proliferation compared with bare nanomotors, which could arise from the local ammonia production and the therapeutic effect of anti-FGFR3. These results hold significant potential for the development of improved targeted cancer therapy and diagnostics using biocompatible nanomotors.

Identifiants

pubmed: 30588798
doi: 10.1021/acsnano.8b06610
doi:

Substances chimiques

Antibodies 0
Polyethylene Glycols 3WJQ0SDW1A
Silicon Dioxide 7631-86-9
Urea 8W8T17847W
FGFR3 protein, human EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3 EC 2.7.10.1
Urease EC 3.5.1.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

429-439

Auteurs

Ana C Hortelão (AC)

Institute for Bioengineering of Catalonia (IBEC) , The Barcelona Institute of Science and Technology (BIST) , Baldiri i Reixac 10-12 , 08028 Barcelona Spain.

Rafael Carrascosa (R)

Institute for Bioengineering of Catalonia (IBEC) , The Barcelona Institute of Science and Technology (BIST) , Baldiri i Reixac 10-12 , 08028 Barcelona Spain.

Nerea Murillo-Cremaes (N)

Institute for Bioengineering of Catalonia (IBEC) , The Barcelona Institute of Science and Technology (BIST) , Baldiri i Reixac 10-12 , 08028 Barcelona Spain.

Tania Patiño (T)

Institute for Bioengineering of Catalonia (IBEC) , The Barcelona Institute of Science and Technology (BIST) , Baldiri i Reixac 10-12 , 08028 Barcelona Spain.

Samuel Sánchez (S)

Institute for Bioengineering of Catalonia (IBEC) , The Barcelona Institute of Science and Technology (BIST) , Baldiri i Reixac 10-12 , 08028 Barcelona Spain.
Institució Catalana de Recerca i Estudis Avancats (ICREA) , Passeig Lluís Companys 23 , 08010 Barcelona , Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH